Elicio Therapeutics (ELTX) Corporate presentation summary

Investment highlights and platform overview

• Developing lymph node-targeted, off-the-shelf cancer immunotherapies using the AMP platform, designed to generate robust immune responses by targeting lymph nodes, the central hub of immune activation.

• Proof-of-concept demonstrated in two completed Phase 1 trials and a randomized Phase 2 trial, with ELI-002 targeting KRAS mutations present in 25% of solid tumors.

• Randomized Phase 2 monotherapy in pancreatic cancer showed findings supporting a precision medicine Phase 3, with multiple complete responses observed in recurrent metastatic PDAC patients after subsequent checkpoint inhibitor combination.

• Value-creating catalysts include initiation of a Phase 1 trial in metastatic PDAC, preparation for Phase 3 in adjuvant PDAC, and investigator-initiated trials in neoadjuvant settings.

Clinical pipeline and strategy

• Pipeline includes ELI-002 7P for mKRAS PDAC in adjuvant, metastatic, and neoadjuvant settings, with additional candidates targeting mBRAF and mTP53 for other solid tumors.

• Near-term focus is on Phase 1 and Phase 3 development in PDAC, with future expansion opportunities in other mKRAS-positive cancers.

• Staged development pathway for ELI-002 7P + RAS inhibitor +/- checkpoint inhibitor in metastatic PDAC, with rapid readouts and capital-efficient small cohorts.

Clinical results and differentiation

• ELI-002 7P demonstrated multiple confirmed complete responses in metastatic PDAC patients, a rare outcome in this setting, especially in MSS/MMR-proficient disease.

• Complete responses were observed after ELI-002 7P treatment followed by nivolumab-based therapy, with durable responses and persistence of mKRAS-specific T cells.

• T cell infiltration and modulation of tumor PD-L1 were observed after ELI-002 7P, suggesting immune priming and tumor microenvironment modulation.

• Complete responses were associated with polyfunctional, personalized T cell responses and antigen spreading, indicating broad anti-tumor immunity.